ePrivacy and GPDR Cookie Consent management by TermsFeed Privacy Generator
Agustín Oterino Durán

Dr. Agustín Oterino Durán

Neurólogo

QUALIFICATIONS

Degree in Medicine; University of Salamanca in 1988
MD in Medicine in the Unviersity of La Laguna in 1997
Master in Management of Health Services; University of Cantabria in 2016
Master in Neuroimmunology; University of Barcelona 2010

 

RESEARCH EXPERIENCE

More than 60 indexed articles in headaches, general neurology and multiple sclerosis
Collaborations in headache and general neurology books
Belonged to expertise panels in headache and multiple sclerosis

 

RESEARCH TRAINING

During the last five y, I have obtained the GCP, and other certificates necessary for
conducting clinical trials type III, IIIb, IV, and II. Last one in 2016, august. 

 

RELEVANT PUBLICATIONS

  1. [Fingolimod: effectiveness and safety in routine clinical practice. An observational, retrospective, multi-centre study in Asturias and Cantabria]. Oterino A, Uria DF, Pena J, Solar D, Villafani J, Oliva-Nacarino P, Suarez-Moro R, Quintanilla VG. Rev Neurol. 2016 Sep 5;63(s01):S19-S26. Spanish. PMID: 27658432. Similar articles. Select item 26916323
  2. [Utility of treatment with atorvastatin 40 mg plus ezetimibe 10 mg versus atorvastatin 80 mg in reducing the levels of LDL cholesterol in patients with ischaemic stroke or transient ischaemic attack]. Palacio E, Viadero-Cervera R, Revilla M, Larrosa-Campo D, Acha-Salazar O, Novo-Robledo, F, Oterino A. Rev Neurol. 2016 Mar 1;62(5):203-10. Spanish. PMID: 26916323 Free Article Similar articles Select item 26395894
  3. Systemic and cerebral endothelial dysfunction in chronic migraine. A case-control study with an active comparator. González-Quintanilla V, Toriello M, Palacio E, González-Gay MA, Castillo J, Montes S, Martínez-Nieto R, Fernandez J, Rojo A, Gutiérrez S, Pons E, Oterino A. Cephalalgia. 2016 May;36(6):552-60. doi: 10.1177/0333102415607857. PMID: 26395894 Similar articles Select item 25581547
  4. Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab. Villar LM, Costa-Frossard L, Masterman T, Fernandez O, Montalban X, Casanova B, Izquierdo G, Coret F, Tumani H, Saiz A, Arroyo R, Fink K, Leyva L, Espejo C, Simó-Castelló M, García-Sánchez MI, Lauda F, Llufriú S, Álvarez-Lafuente R, Olascoaga J, Prada A, Oterino A, de Andrés C, Tintoré M, Ramió-Torrentà L, Rodríguez-Martín E, Picón C, Comabella M, Quintana E, Agüera E, Díaz S, Fernandez-Bolaños R, García-Merino JA, Landete L, Menéndez-González M, Navarro L, Pérez D, Sánchez-López F, Serrano-Castro PJ, Tuñón A, Espiño M, Muriel A, Bar-Or A, Álvarez-Cermeño JC. Ann Neurol. 2015 Mar;77(3):447-57. doi: 10.1002/ana.24345. PMID: 25581547. Similar articles
  5. No evidence of association between common European mitochondrial DNA variants in Alzheimer, Parkinson, and migraine in the Spanish population. Fachal L, Mosquera-Miguel A, Pastor P, Ortega-Cubero S, Lorenzo E, Oterino-Durán A, Toriello M, Quintáns B, Camiña-Tato M, Sesar A, Vega A, Sobrido MJ, Salas A. Am J Med Genet B Neuropsychiatr Genet. 2015 Jan;168B(1):54-65. doi: 10.1002/ajmg.b.32276. PMID: 25349034 Similar articles Select item 24332784